Page 84 - Read Online

Canepa et al. Vessel Plus 2022;6:30 https://dx.doi.org/10.20517/2574-1209.2021.106 Page 11 of 13

failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging 2016;32:1403-13.
DOI PubMed
22. Rapezzi C, Giannini F, Campo G. Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we
progressively unraveling the tangle? Eur J Heart Fail 2021;23:259-63. DOI PubMed
23. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with
severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-87. DOI PubMed PMC
24. Rosenblum H, Masri A, Narotsky DL, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac
amyloidosis. Eur J Heart Fail 2021;23:250-8. DOI PubMed
25. Nitsche C, Scully PR, Patel KP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll
Cardiol 2021;77:128-39. DOI PubMed PMC
26. Nitsche C, Aschauer S, Kammerlander AA, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis:
prevalence, screening possibilities, and outcome. Eur J Heart Fail 2020;22:1852-62. DOI PubMed PMC
27. Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients
referred for transcatheter aortic valve implantation. Eur Heart J 2020;41:2759-67. DOI PubMed PMC
28. Tini G, Sessarego E, Benenati S, et al. Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different
conditions: methodological issues and clinical implications. Eur J Clin Invest 2021;51:e13665. DOI PubMed
29. Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an
initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 2020;300:191-5. DOI PubMed
30. Cariou E, Bennani Smires Y, Victor G, et al; Toulouse Amyloidosis Research Network collaborators*. Diagnostic score for the
detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis. Amyloid 2017;24:101-9. DOI
PubMed
31. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of
America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of
the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac
Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23:352-80. DOI PubMed
32. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342-56. DOI PubMed
PMC
33. Steinberg BA, Zhao X, Heidenreich PA, et al; Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in
patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation
2012;126:65-75. DOI PubMed
34. Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res 2021;128:1421-34. DOI PubMed
35. Chamberlain AM, St Sauver JL, Gerber Y, et al. Multimorbidity in heart failure: a community perspective. Am J Med 2015;128:38-45.
DOI PubMed PMC
36. Vaduganathan M, Patel RB, Michel A, et al. Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol
2017;69:556-69. DOI PubMed
37. Di Lenarda A, Scherillo M, Maggioni AP, et al. Current presentation and management of heart failure in cardiology and internal
medicine hospital units: a tale of two worlds--the TEMISTOCLE study. Am Heart J 2003;146:735. DOI PubMed
38. Miró Ò, Gil VÍ, Martín-Sánchez FJ, et al; Research Group on Acute Heart Failure of the Spanish Society of Emergency Medicine
(ICA-SEMES Research Group) Researchers. Short-term outcomes of heart failure patients with reduced and preserved ejection
fraction after acute decompensation according to the final destination after emergency department care. Clin Res Cardiol
2018;107:698-710. DOI PubMed
39. Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV. Care and outcomes of patients newly hospitalized for heart failure in the
community treated by cardiologists compared with other specialists. Circulation 2003;108:184-91. DOI PubMed
40. Uthamalingam S, Kandala J, Selvaraj V, et al. Outcomes of patients with acute decompensated heart failure managed by cardiologists
versus noncardiologists. Am J Cardiol 2015;115:466-71. DOI PubMed
41. Selim AM, Mazurek JA, Iqbal M, Wang D, Negassa A, Zolty R. Mortality and readmission rates in patients hospitalized for acute
decompensated heart failure: a comparison between cardiology and general-medicine service outcomes in an underserved population.
Clin Cardiol 2015;38:131-8. DOI PubMed PMC
42. Ricciardi E, La Malfa G, Guglielmi G, et al. Characteristics of current heart failure patients admitted to internal medicine vs.
cardiology hospital units: the VASCO study. Intern Emerg Med 2020;15:1219-29. DOI PubMed
43. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with
preserved ejection fraction. N Engl J Med 2006;355:251-9. DOI PubMed
44. Ponikowski P, Voors AA, Anker SD, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European
Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
2016;37:2129-200. DOI PubMed
45. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved
ejection fraction. N Engl J Med 2021;385:1451-61. DOI PubMed
46. Oghina S, Bougouin W, Bézard M, et al. The impact of patients with cardiac amyloidosis in HFpEF trials. JACC Heart Fail